Beijing, China

Haibo Han

USPTO Granted Patents = 1 


Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2019

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Haibo Han: Innovator in Cancer Research

Introduction

Haibo Han is a prominent inventor based in Beijing, China. He has made significant contributions to the field of cancer research, particularly in the identification and treatment of tumor-initiating cells. His innovative work has led to the development of a valuable patent that addresses critical challenges in oncology.

Latest Patents

Haibo Han holds a patent for an "Antibody and binding fragment recognizing CACNA2D1 and use thereof." This patent discloses a method for searching, identifying, or validating CACNA2D1 as a marker for tumor-initiating cells. The method involves immunizing an animal using HEP-12 cells, which originate from a recurrent tumor and are rich in originating cells. Additionally, the patent describes a monoclonal antibody that specifically recognizes CACNA2D1 or its antigen-binding fragments, along with its application in treating or preventing tumors or diseases related to CACNA2D1. He has 1 patent to his name.

Career Highlights

Haibo Han is affiliated with the Beijing Institute for Cancer Research, where he conducts his research and development activities. His work is instrumental in advancing the understanding of cancer biology and improving therapeutic strategies.

Collaborations

Haibo Han collaborates with esteemed colleagues, including Zhiqian Zhang and Wei Zhao, who contribute to his research endeavors and enhance the impact of his work in the field of cancer research.

Conclusion

Haibo Han's innovative contributions to cancer research, particularly through his patent on CACNA2D1, highlight his role as a key inventor in the field. His work not only advances scientific knowledge but also holds promise for improving cancer treatment options.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…